Amid Booming Demand, Serum Institute Of India Looking To Begin Production of Covishield Overseas
As Covid-19 Cases Rise, Serum Institute Plans To Begin Overseas Production Of Covishield Vaccine: ReportSII's Covishield vaccine (Pic Via Twitter)

Pune based Serum Institute of India (SII) is said to be looking at boosting the supply of Covishield COVID-19 vaccine by initiating production at other facilities outside of India, as it is presently struggling to meet the supply commitments, reports Livemint.

An announcement is expected to be made by the company in this regard in the next few days, SII CEO Adar Poonawalla was quoted as saying by The Times on Friday (30 April).

The development comes at a time when the demand for Covishield in India has skyrocketed with the surging fresh wave of COVID-19 cases and the opening up of the vaccination to those aged between 18 and 44 years.

Meanwhile, it should be noted that just last week, Poonawalla had also said that SII will be able to raise its monthly production to 100 million doses by July only, which is later than the earlier timeline of May end.

Poonawalla hopes to increase the production to as much as 2.5 to three billion doses a year within the next six months.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber